Agents and Actions

, Volume 35, Issue 1–2, pp 96–103 | Cite as

Effects of the immunomodulator diacetyl-splenopentin on antigen-induced arthritis in rabbits

  • R. Bräuer
  • K. Thoss
  • S. Henzgen
  • G. Waldmann
Inflammation and Immunomodulation


Long-term treatment with the immunomodulator diacetyl-splenopentin reduces the severity of chronic joint inflammation and cartilage destruction in rabbits with antigen-induced arthritis. The level of specific antibodies as well as specific and non-specific cell-mediated immune reactivities including the proliferative response of spleen lymphocytes to cartilage proteoglycans in treated animals are lower than in untreated arthritic rabbits. Moreover, suppressor cell activity, which normally decreases during the early phase of inflammation, is enhanced and hyperreactive helper cell potential is reduced. These findings suggest that treatment with diacetyl-splenopentin normalizes the immune regulation, which is disturbed in the early phase of inflammation. This might result in a depression of the hyperreactive immune system including the autoimmunity developed against cartilage. Lowered immune reactivity in the joint in turn reduces the severity of chronic joint inflammation.


Immune Reactivity Arthritis Cell Activity Early Phase Specific Antibody 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    I. M. Hunneyball and D. R. Stanworth,Immunological models of rheumatoid arthritis with particular reference to the rabbit., IRCS J. Med. Sci.9, 1–4 (1981).Google Scholar
  2. [2]
    I. M. Hunneyball,Use of experimental arthritis in the rabbit for the development of antiarthritic drugs. Adv. Inflamm. Res.7, 249–262 (1984).Google Scholar
  3. [3]
    D. C. Dumonde and L. E. Glynn,The production of arthritis in rabbits by an immunological reaction to fibrin. Br. J. Exp. Pathol.43, 373–383 (1962).PubMedGoogle Scholar
  4. [4]
    L. E. Glynn,The chronicity of inflammation and its significance in rheumatoid arthritis. Ann. Rheum. Dis.27, 105–121 (1968).PubMedGoogle Scholar
  5. [5]
    M. E. Steinberg, C. R. McCrae, L. D. Cohen and H. R. Schumacher,Pathogenesis of antigen-induced arthritis. Clin. Orthop. Relat. Res.97, 248–260 (1973).PubMedGoogle Scholar
  6. [6]
    V. M. Goldberg, E. M. Lange and P. Davis,Experimental immune synovitis in the rabbit. Relative role of cell mediated and humoral immunity. Arthritis Rheum.17, 993–1005 (1974).PubMedGoogle Scholar
  7. [7]
    E. R. Pettipher and B. Henderson,The relationship between cell-mediated immunity and cartilage degradation in antigen-induced arthritis in the rabbit. Br. J. Exp. Pathol.69, 113–122 (1988).PubMedGoogle Scholar
  8. [8]
    R. Bräuer, K. Thoss, S. Henzgen and G. Waldmann,Significance of cell-mediated and humoral immunity in the acute and chronic phase of antigen-induced arthritis in rabbits. Exp. Pathol.14, 197–208 (1988).Google Scholar
  9. [9]
    B. R. Champion and A. R. Poole,Immunity to homologous cartilage proteoglycans in rabbits with chronic inflammatory arthritis. Collagen Relat. Res.1, 453–473 (1981).Google Scholar
  10. [10]
    T. F. Kresina, I. A. Rosner, V. M. Goldberg and R. W. Moskowitz,Immunoglobulin G-induced experimental chronic immune synovitis: cell-mediated immunity to native interstitial collagen molecules and their constituent polypeptide chains. Cell. Immunol.87, 504–516 (1984).CrossRefPubMedGoogle Scholar
  11. [11]
    J. U. Yoo, T. F. Kresina, C. J. Malemund and V. M. Goldberg,Epitopes of proteoglycans eliciting an anti-proteolgycan response in chronic immune synovitis. Proc. Nat. Acad. Sci. USA84, 832–836 (1987).PubMedGoogle Scholar
  12. [12]
    T. F. Kresina, J. U. Yoo and V. M. Goldberg,Evidence that a humoral immune response to autologous cartilage proteoglycan can participate in the induction of cartilage pathology. Arthritis Rheum.31, 248–257 (1988).PubMedGoogle Scholar
  13. [13]
    R. Bräuer, S. Henzgen, K. Thoss and G. Waldmann,Changes of immunoregulatory properties and induction of autoimmune reactivity to cartilage in rabbits with antigen-induced arthritis. Exp. Pathol.40, 35–44 (1990).PubMedGoogle Scholar
  14. [14]
    G. Goldstein and T. K. Audhya,Thymopoietin to thymopentin: experimental studies. Survey Immunol. Res.4, suppl. 1, 1–10 (1985).Google Scholar
  15. [15]
    W. Diezel, R. Eckert, H.-D. Volk, S.-R. Goan, K. Forner, R. von Baehr, N. Sönnichsen and P. Oehme,Splenopentin-Biologische Wirkungen und therapeutische Aspekte. Z. Klin. Med.42, 15–18 (1987).Google Scholar
  16. [16]
    M. E. J. Billingham,Models of arthritis and the search for anti-arthritic drugs. Pharmacol. Ther.21, 389–428 (1983).CrossRefPubMedGoogle Scholar
  17. [17]
    M. J. Crossley, M. Spowage and I. M. Hunneyball,Studies of the effects of pharmacological agents on antigen-induced arthritis in Balb/c mice. Drugs Exp. Clin. Res.13, 273–277 (1987).PubMedGoogle Scholar
  18. [18]
    W. Diezel, R. Eckert, K. Forner and S. Gruner,Functional effects of splenin 32–34 on antibody formation in immunosuppressed mice. Biomed. Biochim. Acta10, 1349–1352 (1986).Google Scholar
  19. [19]
    R. Eckert, W. Diezel, K. Forner, U. Pfüller and R. von Baehr,Histamine receptor bearing lymphocytes (HRL): splenopentin-accelerated reconsitution of the immunoresponsiveness after elimination of HRL. All. Immunol.32, 267–270 (1986).Google Scholar
  20. [20]
    H. A. Weber, J. Maciejewski, R. Eckert, M. Schütt, W. Diezel and H.-D. Volk,Splenopentin (DAc-SP-5) accelerates the restoration of myelopoietic and immune systems after sublethal radiation in mice. Int. J. Immunopharmacol.12, 761–768 (1990).CrossRefPubMedGoogle Scholar
  21. [21]
    E. M. Veys, E. C. Huskinsson, M. Rosenthal, T. L. Vischer, H. Mielants, P. A. Thrower, J. Scott, H. Ott, H. Scheijgrond and J. Symonens,Clinical response to therapy with thymopoietin pentapeptide (TP-5) in rheumatoid arthritis. Ann. Rheum. Dis.41, 441–443 (1982).PubMedGoogle Scholar
  22. [22]
    M. Malaise, P. Franchimont, C. Hauwaert, B. Danneskiold-Samsoe, D. Gross, H. Gerber, H. Gerschpacher and K. Bolla,Interim results on the clinical effects of i.v. administered thymopentin in active rheumatoid arthritis. Int. J. Clin. Pharmacol. Res.4, 451–457 (1984).PubMedGoogle Scholar
  23. [23]
    L. Molin, F. Schmid and K. Bolla,First observations on high-dosed and long-term thymopentin treatment in active rheumatoid arthritis. Int. J. Clin. Pharmacol. Res.4, 445–449 (1984).PubMedGoogle Scholar
  24. [24]
    M. G. Malaise, C. Hauwaert, P. Franchimont, B. Danneskiold-Samsoe, R. Bach-Andersen, D. Gross, H. Gerber, H. Gerschpacher, H. Stocker and K. Bolla,Treatment of active rheumatoid arthritis with slow intravenous injections of thymopentin. A double-blind placebo-controlled randomised study. Lancet 1985/I, 832–836 (1985).Google Scholar
  25. [25]
    L. Molin, F. Schmid and K. Bolla,Some observations on various dose regimens of thymopentin treatment in rheumatoid arthritis. Survey Immunol. Res.4, suppl. 1, 76–80 (1985).Google Scholar
  26. [26]
    E. M. Lemmel, G. L. Bach, W. Bolten, D. Brackertz, Z. Fahmy, H. Mattern, I. Stroehmann and A. Wittenborg,Immunmodulierende Therapie der chronischen Polyarthritis mit Thymopentin. Eine multizentrische placebokontrollierte Studie an 119 Patienten. Dtsch. med. Wschr.113, 172–176 (1988).PubMedGoogle Scholar
  27. [27]
    G. Bodini, A. Luisa and A. Quadri,Clinical effects of thymopentin (Timunox) in patients with active rheumatoid arthritis. Int. J. Immunother.5, 129–131 (1989).Google Scholar
  28. [28]
    E. M. Veys, P. Hermanns, G. Goldstein, P. Kung, J. Schindler and J. van Wauwe,Determination of T lymphocyte subpopulations by monoclonal antibodies in rheumatoid arthritis. Influence of immunomodulating agents. Int. J. Immunopharmacol.3, 313–319 (1981).CrossRefPubMedGoogle Scholar
  29. [29]
    E. M. Veys, H. Mielants, G. Verbruggen, T. Spiro, E. Newdeck, D. Power and G. Goldstein,Thymopoietein pentapeptide (thymopentin, TP-5) in the treatment of rheumatoid arthritis. A compilation of several short- and longterm clinical studies. J. Rheumatol.11, 462–466 (1984).PubMedGoogle Scholar
  30. [30]
    M. Bardare, F. Corona, M. T. Ogliari and E. Cohen,Thymopentin in the treatment of juvenile chronic arthritis. Clin. Exp. Rheumatol.8, 89–93 (1990).Google Scholar
  31. [31]
    R. Colle, T. Ceschia, A. Colatutto and F. Biffoni,Use of thymopentin in autoimmune hemolytic anemia due to chronic lymphocytic leukemia. Curr. Therap. Res.44, 1045–1049 (1988).Google Scholar
  32. [32]
    M. G. Bernengo, G. C. Doveil, M. Meregalli, A. Appino and R. Massobrio,Immunomodulation and Sèzary syndrome: experience with thymopentin (TP-5). Br. J. Dermatol.119, 207–221 (1988).PubMedGoogle Scholar
  33. [33]
    J. DeMaubeuge, E. Haneke, D. Djawari, K. Wolff, G. Stingl, L. Molin, E. Schöpf, R. Stengel, H. Degreef, E. Panconesi, B. Wüthrich and K. Bolla,Thymopentin treatment in Herpes simplex infection: an open, monitored, multicenter study. Survey Immunol. Res.4, suppl. 1, 30–36 (1985).Google Scholar
  34. [34]
    M. B. Sztein and A. L. Goldstein,Thymic hormones — a clinical update. Springer Semin. Immunopathol.9, 1–18 (1986).CrossRefPubMedGoogle Scholar
  35. [35]
    S. Kato and H. Nakamura,Suppression of acute experimental allergic encephalomyelitis by synthetic serum thymic factor. Clinical, histopathological, and immunohistochemical studies. Acta Neuropathol.75, 337–344 (1988).CrossRefPubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag 1992

Authors and Affiliations

  • R. Bräuer
    • 1
  • K. Thoss
    • 1
  • S. Henzgen
    • 1
  • G. Waldmann
    • 1
  1. 1.Institute of PathologyFriedrich Schiller UniversityJenaFederal Republik of Germany

Personalised recommendations